Authors: Sylvie Lorenzen Ben Panzram Gisela Keller Florian Lordick Ken Herrmann Karin Becker Ruppert Langer Markus Schwaiger Jorg Rudiger Siewert Katja Ott
Publish Date: 2010/05/07
Volume: 13, Issue: 1, Pages: 178-186
Abstract
The MUNICON trial confirmed prospectively the usefulness of early response evaluation by 2deoxy2F18fluoroDglucosepositron emission tomography FDGPET Metabolic responders R showed initially a higher FDG uptake compared with nonresponders p = 0018 An association of the vascular endothelial growth factor VEGF 936CT polymorphism and FDG uptake was reported for breast cancer Therefore we investigated the VEGF 936CT polymorphism for an association with response and survivalThe study was based on 110 patients included in the MUNCON trial 103 male seven female 75 AEG I 35 AEG II eventfree survival EFS median 211 ± 46 months Response was significantly associated with EFS The VEGF 936CT polymorphism was determined by PCR and restriction fragment length polymorphism analysis For analysis the Tvariants were combinedOne hundred two patients were evaluable Seventytwo patients showed the CC 24 the CT and six the TT genotype Median EFS was 293 months for CC and 117 months for CT/TT p = 004 No association of the genotypes CC or CT/TT with the SUV or response was found Multivariate analysis revealed histopathological regression p = 0003 and genotype p = 004 as independent prognostic factors A combination of genotype and PET response GenPET defines three prognostic groups early in the course of treatment p = 0002 Cox regression analysis including clinical and histopathological response and GenPET reveals GenPET as independent prognostic factor p = 0003The VEGF 936CT polymorphism is a prognostic factor in patients undergoing neoadjuvant chemotherapy although it is not associated with FDG uptake and response The combination of metabolic response and VEGF 936CT polymorphism defines three different prognostic groups These findings need to be confirmed prospectively
Keywords: